DBV Technologies S.A. (NASDAQ:DBVT) had its target price dropped by stock analysts at Barclays PLC from $58.00 to $30.00 in a report issued on Monday. The brokerage currently has an “overweight” rating on the stock. Barclays PLC’s target price points to a potential downside of 37.59% from the stock’s current price.

Several other equities research analysts have also weighed in on DBVT. ValuEngine lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, June 30th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of DBV Technologies in a report on Thursday, July 6th. Morgan Stanley reissued an “overweight” rating on shares of DBV Technologies in a report on Monday, July 10th. BidaskClub raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research raised shares of DBV Technologies from a “sell” rating to a “hold” rating and set a $49.00 price objective on the stock in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $51.63.

DBV Technologies (NASDAQ DBVT) traded down 43.67% on Monday, reaching $27.08. 12,093,801 shares of the company’s stock were exchanged. DBV Technologies has a 12 month low of $22.33 and a 12 month high of $50.57. The firm has a 50-day moving average of $44.94 and a 200-day moving average of $39.47. The firm’s market capitalization is $1.25 billion.

COPYRIGHT VIOLATION NOTICE: “DBV Technologies S.A. (DBVT) PT Lowered to $30.00” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/23/dbv-technologies-s-a-dbvt-pt-lowered-to-30-00.html.

A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC bought a new stake in DBV Technologies during the 2nd quarter worth about $90,724,000. Jennison Associates LLC boosted its stake in shares of DBV Technologies by 86.4% in the 2nd quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock valued at $35,784,000 after purchasing an additional 464,341 shares during the last quarter. Morgan Stanley boosted its stake in shares of DBV Technologies by 89.9% in the 1st quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after purchasing an additional 118,317 shares during the last quarter. Sectoral Asset Management Inc boosted its stake in shares of DBV Technologies by 34.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock valued at $6,398,000 after purchasing an additional 45,653 shares during the last quarter. Finally, Exane Asset Management boosted its stake in shares of DBV Technologies by 3.9% in the 2nd quarter. Exane Asset Management now owns 143,000 shares of the company’s stock valued at $5,107,000 after purchasing an additional 5,394 shares during the last quarter. 45.52% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.